PGC set up the bioinformatics center to complement its existing next-generation sequencing work.
When IBM was preparing its artificial-intelligence program Watson to compete on the game show "Jeopardy!," it made the system read Wikipedia. The training worked and Watson beat its human competitors. Now IBM and the New York Genome Center are testing whether making Watson read PubMed can help defeat cancer.
A team from IBM Research and the Institute of Bioengineering and Nanotechnology in Singapore have designed a Vitamin E-based hydrogel that can release Roche's cancer antibody Herceptin under the skin for several weeks.
Having updated its disease-modeling platform last week, tech giant IBM has now snagged a grant to dig into electronic health records to predict heart disease and opened a Big Data research lab.
Belgian biopharma group UCB has partnered with IBM to provide physicians with a predictive tool for use in treating epileptic patients, and the company has worked on expanding its offerings after patents expired on its epilepsy drug Keppra.
IBM has landed a 5-year $75 million FDA contract to help the agency modernize its regulatory review process by ramping up the agency's computation science capabilities.
As researchers team up with collaborators outside their own labs, software and tech providers are trotting out all kinds of new tools and products to support external R&D arrangements among pharma groups and others in life sciences. And the Bio-IT World Expo here in Boston is shaping up to be a prime spot to announce new products and tech deals.
The spread of Big Data throughout the global life sciences industry continued this week, with two deals showing Eastern Europe is alert to the possibilities. In Poland, an IBM supercomputer is to crunch chronic disease data, while Hungary-based ChemAxon extended a deal with Core Informatics.
As software providers know well, AstraZeneca has been one of the most prolific users of information technology in the pharma world. So the drugmaker's IT preferences and activities garner attention, including the messy court showdown between the company and IBM.
IBM has made some headlines about an antimicrobial hydrogel, which could come to the rescue of hospitals and patients grappling with drug-resistant bugs. But Big Blue ($IBM) appears to have a long way to go before the technology becomes a force in biotech, where progress is often counted in decades rather than years.